Clinical trial · Interventional
Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease Survivors
A Feasibility Study of Tamoxifen Prevention of Breast Cancer in Hodgkin's Disease Survivors
NCT00165308CI-TRIAL-00015044completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is determine whether or not tamoxifen reduces the chance of Hodgkin's Disease survivors developing breast cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Hodgkin's Disease | Hodgkin Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Tamoxifen | Drug | Tamoxifen | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Tamoxifen
- description
- Single arm: Tamoxifen 20mg daily
- interventionNames
- Drug: Tamoxifen
Primary outcomes (1)
- measure
- To determine the feasibility of a randomized trial testing the effectiveness of tamoxifen in reducing the risk of radiogenic breast cancer.
- timeFrame
- 2 years
Secondary outcomes (1)
- measure
- To determine the safety and effect on quality of life in participating women.
- timeFrame
- 2 years
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 35 Years
Show eligibility criteria text
Inclusion Criteria: * Females diagnosed with Hodgkin's Disease at age \< 35 years * \> 5 years from mantle or chest radiation * Current age \> 30 years * Has completed childbearing * Willingness to discontinue use of oral contraceptives or other hormonal contraception for duration of the study Exclusion Criteria: * History of secondary malignancy after Hodgkin's disease, except thyroid cancer of basal cell cancer * Recurrence of Hodgkin's disease in the 5 years before study entry * Current participation in any other cancer prevention study * Current or prior use of tamoxifen * Current use of coumadin * History of deep venous thrombosis, pulmonary embolism, or a condition known to be associated with hypercoagulability * History of cerebrovascular accident * History of macular degeneration * Current use of chemotherapy for benign disease
References
Publications (1)
- DERIVEDBoucher AA, Blaes AH. Prophylactic mastectomy: a treatment alternative for Hodgkin survivors? Clin Breast Cancer. 2013 Oct;13(5):307-8. doi: 10.1016/j.clbc.2013.06.001. Epub 2013 Jul 26. No abstract available. PMID 23891588